Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

Phase 1 Completed 11 enrolled Stanford University National Comprehensive Cancer Network · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to find out the maximum tolerated dose (MTD) of bortezomib (VELCADE) in combination with pralatrexate in patients with previously treated multiple myeloma, AL amyloid and Waldenstroem's macroglobulinemia.

Timeline

Start: 2010-08
Primary completion: 2014-02
Completion: —

Publications

Dunn TJ, Dinner S, Price E, Coutre SE, Gotlib J, Hao Y, Berube C, Medeiros BC, Liedtke M. A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2016 Apr;173(2):253-9. doi: 10.1111/bjh.13946. Epub 2016 Apr 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.3 mg/m2	Intravenous
Subject	Pralatrexate	Other / unclassified	10 mg/m2	Intravenous
Subject	Pralatrexate	Other / unclassified	30 mg/m2	Intravenous

Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

Summary

Timeline

Publications

Drugs

Indications